Forecast

The analysts' average price target is €3.49 (+223.15%). The median is €3.49 (+223.15%).

Buy	2
Hold	0
Sell	0

News Go to news feed

Vivani Medical completes recruitment for semaglutide implant, top-line data expected in November 2026

Vivani Medical has completed recruitment and dosing for the phase‑I SLIM‑1 study of a semaglutide implant and expects top‑line results in November 2026. The company stresses that its small NanoPortal implant could address adherence, gastrointestinal side effects and frequent dosing, aiming for once- to twice-yearly administration. Vivani cites preclinical data showing sustained release and effects in weight‑loss models, a technology assessment with Novo Nordisk and an upcoming merger of Cortigent with ClearOne in Q3 2026. It also points to strong competition in the obesity market, dropout rates and potential tolerability risks of current GLP‑1 therapies. » More on de.investing.com

Financials

In the last quarter, VIVANI MEDICAL INC had revenue of €0 and net profit of -€5.58m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-5.58m	7.91%
EBITDA	-6.46m	8.20%

Fundamentals

Metric	Value
Market capitalization	€95.51m
Number of shares	86.24m
52-week high/low	€1.67 - €0.80
Dividends	No
Beta	3.28
P/E ratio	-3.63
PEG ratio	-0.14
P/B ratio	5.83
P/S ratio	0.00

Company profile

Vivani Medical, Inc., ein Unternehmen in der klinischen Phase, entwickelt verschiedene Implantate zur Behandlung chronischer Krankheiten mit hohem ungedecktem medizinischen Bedarf. Das Unternehmen entwickelt ein Portfolio von Miniatur-Arzneimittelimplantaten, die minimal schwankende Arzneimittelprofile liefern, sowie implantierbare Sehprothesen, die blinden Menschen ein nützliches künstliches Sehvermögen verleihen. Der Hauptsitz des Unternehmens befindet sich in Emeryville, Kalifornien.